Table 3

Association between CAN status at DCCT closeout and subsequent CVD events

No CAN, n = 1,262CAN, n = 131UnadjustedMinimally adjustedFully adjustedFully adjusted + HbA1c
Patients, n (%)*Events, nPatients, n (%)*Events, nHR (95% CI),P value
Any CVD event132 (10)24433 (25)552.79 (1.91–4.09), <0.00012.08 (1.41–3.07), 0.00021.53 (1.01–2.32), 0.04681.53 (1.01–2.32), 0.0474
 Nonfatal acute myocardial infarction36 (3)419 (7)9
 Nonfatal cerebrovascular event16 (1)184 (3)4
 Death from CVD13 (1)134 (3)4
 Silent myocardial infarction37 (3)396 (5)6
 Confirmed angina26 (2)327 (5)9
 Revascularization63 (5)9618 (14)20
 Congestive heart failure7 (1)82 (2)3
Nonfatal myocardial infarction or stroke or death from CVD (MACE)59 (5)7216 (12)172.93 (1.68–5.09), 0.00012.08 (1.18–3.66), 0.01101.78 (0.98–3.24), 0.06031.56 (0.84–2.88), 0.1566
 Nonfatal acute myocardial infarction36 (3)419 (7)9
 Nonfatal cerebrovascular event16 (1)184 (3)4
 Death from CVD13 (1)134 (3)4
  • *Number of patients with each type of event regardless of whether or not it is the initial event for that subject.

  • †Cox proportional hazards regression models for the time to the first CVD event following DCCT closeout, unadjusted; minimally adjusted for DCCT closeout age; fully adjusted to also include DCCT treatment group, primary prevention vs. secondary intervention cohort, DCCT closeout duration of diabetes, systolic and diastolic blood pressure, total cholesterol, triglycerides, and microalbuminuria; fully adjusted to also include EDIC updated mean HbA1c. The following covariates were entered into each model as time-dependent covariates: systolic and diastolic blood pressure, total cholesterol, triglycerides, microalbuminuria, and EDIC updated mean HbA1c.